One of the world’s largest commercial developers of HIV drugs is working on a treatment that can be injected by patients at home every two to three months by the end of the decade, saving them frequent visits to the clinic.
ViiV Healthcare, a GlaxoSmithKline-controlled joint venture, makes 17 prescription HIV medicines, including the long-acting treatment cabotegravir, which was first approved in the US in January 2021.
